Cost-Effectiveness of Tafamidis Therapy for Transthyretin Amyloid Cardiomyopathy

BACKGROUND: In patients with transthyretin amyloid cardiomyopathy (ATTR-CM), tafamidis reduces all-cause mortality and cardiovascular hospitalizations, and slows decline in quality-of-life compared with placebo. In May 2019, tafamidis received expedited approval from the US FDA as a breakthrough dru...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Circulation
मुख्य लेखकों: Kazi, Dhruv S., Bellows, Brandon K., Baron, Suzanne J., Shen, Changyu, Cohen, David J., Spertus, John A., Yeh, Robert W., Arnold, Suzanne V., Sperry, Brett W., Maurer, Mathew S., Shah, Sanjiv J.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: 2020
विषय:
Article
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC7156331/
https://ncbi.nlm.nih.gov/pubmed/32078382
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन